EGFR and non-small cell lung carcinoma: In contrast, EGFRm-negative NSCLC patients (who are not considered to benefit from EGFR-TKI therapy), our analysis suggested a possibility that choice of treatment based on healthcare coverage status may also influence survival, and this possibility may need to be explored in future work.